



## **NGM Bio to Host Conference Call to Discuss Interim Results from Ongoing 24-Week Phase 2 Study of Aldafermin (NGM282) in Patients with NASH**

October 6, 2019

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, October 7, 2019 at 8:30 a.m. ET (5:30 a.m. PT) to discuss preliminary results from a planned, pre-specified interim analysis of the aldafermin 1 mg Cohort 4 in the ongoing, adaptive Phase 2 study of aldafermin (NGM282) in patients with non-alcoholic steatohepatitis (NASH).

Conference call and webcast details are as follows:

### **Live Conference Call**

Domestic Callers: (844) 873-0551  
International Callers: (602) 563-8472  
Passcode: 7077749

### **Live and Archived Webcast**

For the live or archived webcast, please visit the "Investors & Media" section of NGM's website at <https://ir.ngmbio.com/>. The webcast will be archived for 30 days.

### **Archived Conference Call**

Domestic Callers: (855) 859-2056  
International Callers: (404) 537-3406  
Passcode: 7077749

The archived conference call will be available for 30 days.

### **About NGM Biopharmaceuticals, Inc.**

NGM is a clinical stage biopharmaceutical company focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company leverages its biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable it to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. NGM aspires to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit <http://www.ngmbio.com> for more information.

### **Investor Contact:**

Sylvia Wheeler  
[swheeler@wheelhousesa.com](mailto:swheeler@wheelhousesa.com)  
[ir@ngmbio.com](mailto:ir@ngmbio.com)

### **Media Contact:**

Liz Melone  
[media@ngmbio.com](mailto:media@ngmbio.com)